drugset / Trial / NCT06498518
A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
Trial to investigate if the addition of two novel immunotherapy agents in combination with a chemotherapy agent can reduce the size of the cancer and how long they can delay the growth of the cancer in patients with metastatic pancreatic cancer.
Timeline
- Start
- 2024-06-17
- Primary completion
- 2025-05-23
- Completion
- 2025-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM-101 | Other / unclassified | 1 mg | Other |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |